Hepatobiliary disease in inflammatory bowel disease

Area of Science:

• Gastroenterology and Hepatology
• Immunology
• Genetics

Background:

• Hepatobiliary diseases frequently occur in patients with Inflammatory Bowel Disease (IBD).
• Primary Sclerosing Cholangitis (PSC) is the most prevalent, affecting approximately 7.5% of ulcerative colitis (UC) patients.
• The etiology of PSC remains unclear, though genetic susceptibility and shared immunologic abnormalities with UC are implicated.

Purpose of the Study:

• To summarize the current understanding of hepatobiliary diseases in IBD patients, with a focus on PSC.
• To outline diagnostic approaches for PSC.
• To review current treatment strategies and complications associated with PSC.

Main Methods:

• Diagnosis of PSC is typically established through characteristic cholangiogram findings in patients with abnormal liver function tests.
• Liver biopsy may be utilized for diagnosing small duct PSC in cases with normal cholangiograms.
• Review of existing literature on PSC management and associated complications.

Main Results:

• Currently, no medications effectively treat PSC.
• Endoscopic dilation of dominant strictures can decrease cholangitis frequency and potentially improve survival.
• Orthotopic liver transplantation (OLT) is the only established treatment for advanced PSC.
• Cholangiocarcinoma is a serious, difficult-to-diagnose complication of PSC.
• Other less frequent hepatobiliary disorders in IBD include cholelithiasis, primary biliary cholangitis (PBC), portal vein thrombosis, and hepatic abscess.

Conclusions:

• PSC is a significant hepatobiliary complication in IBD, particularly UC, with complex diagnosis and limited treatment options.
• Management strategies focus on symptomatic relief, stricture dilation, and OLT for advanced disease.
• Vigilance for complications like cholangiocarcinoma is crucial in PSC patients.